Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Disruption of fibronectin fibrillogenesis affects intraocular pressure (IOP) in BALB/cJ mice.

Tytuł:
Disruption of fibronectin fibrillogenesis affects intraocular pressure (IOP) in BALB/cJ mice.
Autorzy:
Faralli JA; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.
Filla MS; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.
McDowell CM; Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.
Peters DM; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.; Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.
Źródło:
PloS one [PLoS One] 2020 Aug 21; Vol. 15 (8), pp. e0237932. Date of Electronic Publication: 2020 Aug 21 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Fibronectins/*metabolism
Intraocular Pressure/*drug effects
Ocular Hypertension/*metabolism
Peptides/*therapeutic use
Trabecular Meshwork/*drug effects
Adolescent ; Adult ; Animals ; Cells, Cultured ; Extracellular Matrix/drug effects ; Extracellular Matrix/metabolism ; Female ; Fibronectins/chemistry ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Ocular Hypertension/chemically induced ; Ocular Hypertension/drug therapy ; Peptides/metabolism ; Peptides/pharmacology ; Trabecular Meshwork/cytology ; Trabecular Meshwork/metabolism ; Transforming Growth Factor beta2/metabolism ; Transforming Growth Factor beta2/toxicity
References:
Jpn J Ophthalmol. 2002 May-Jun;46(3):249-53. (PMID: 12063033)
J Cell Biol. 1990 Aug;111(2):699-708. (PMID: 2380248)
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3897-3913. (PMID: 31529121)
J Biol Chem. 1998 Jan 30;273(5):2601-9. (PMID: 9446562)
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2067-76. (PMID: 19959644)
J Cell Biol. 1998 Aug 10;142(3):873-81. (PMID: 9700173)
J Ocul Pharmacol Ther. 2008 Apr;24(2):175-85. (PMID: 18355131)
Matrix Biol. 2007 Oct;26(8):642-51. (PMID: 17611093)
Cell Adhes Commun. 1996 Sep;4(3):149-58. (PMID: 8969861)
Exp Eye Res. 2018 Jun;171:164-173. (PMID: 29526795)
EMBO J. 1996 Mar 1;15(5):989-98. (PMID: 8605894)
Mol Biol Cell. 2009 Feb;20(3):846-58. (PMID: 19037100)
J Cell Biol. 1989 Aug;109(2):863-75. (PMID: 2527241)
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3437-43. (PMID: 11006236)
Graefes Arch Clin Exp Ophthalmol. 2001 Feb;239(2):109-13. (PMID: 11372538)
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1811-1823. (PMID: 28346614)
J Biol Chem. 1994 Jul 22;269(29):19183-7. (PMID: 8034677)
J Biol Chem. 1997 Jan 17;272(3):1718-24. (PMID: 8999851)
J Cell Sci. 1987 Nov;88 ( Pt 4):419-30. (PMID: 3503900)
Am J Pathol. 2017 Apr;187(4):713-723. (PMID: 28167045)
J Biol Chem. 2001 Jun 29;276(26):23430-9. (PMID: 11323441)
Eur J Pharmacol. 2016 Sep 15;787:32-42. (PMID: 27112663)
Int Ophthalmol. 2004 Jan;25(1):19-22. (PMID: 15085971)
Exp Eye Res. 2015 Dec;141:33-41. (PMID: 26025608)
Invest Ophthalmol Vis Sci. 1979 Oct;18(10):1043-9. (PMID: 383640)
BMC Dev Biol. 2001;1:3. (PMID: 11228591)
PLoS One. 2018 Oct 24;13(10):e0205360. (PMID: 30356276)
Mol Biol Cell. 1996 Nov;7(11):1737-48. (PMID: 8930896)
J Cell Biol. 1994 Dec;127(6 Pt 2):2037-48. (PMID: 7806580)
Mol Biol Cell. 2002 Oct;13(10):3546-59. (PMID: 12388756)
Am J Pathol. 2003 Sep;163(3):1045-56. (PMID: 12937145)
Exp Eye Res. 2009 Apr;88(4):676-82. (PMID: 19087875)
J Biol Chem. 2010 Dec 24;285(52):41087-99. (PMID: 20947497)
Lab Invest. 1981 Aug;45(2):120-9. (PMID: 7022020)
Graefes Arch Clin Exp Ophthalmol. 2001 Mar;239(3):199-207. (PMID: 11405069)
Blood. 1999 May 1;93(9):2984-90. (PMID: 10216094)
Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):858-64. (PMID: 20720229)
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):173-81. (PMID: 25957840)
J Hepatol. 2015 Mar;62(3):625-33. (PMID: 24946284)
Biochem J. 2013 Dec 1;456(2):283-95. (PMID: 24070235)
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3743-57. (PMID: 26066743)
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):226-34. (PMID: 16384967)
J Cell Biol. 1989 Aug;109(2):903-14. (PMID: 2760116)
Biochem Cell Biol. 1996;74(6):745-8. (PMID: 9164644)
Exp Eye Res. 2009 Apr;88(4):689-93. (PMID: 18835267)
Mol Biol Cell. 1997 Aug;8(8):1415-25. (PMID: 9285815)
J Cell Biol. 1998 Apr 20;141(2):539-51. (PMID: 9548730)
Vision Res. 1981;21(1):155-60. (PMID: 7269287)
Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):1074-9. (PMID: 19407246)
J Cell Biol. 1983 Aug;97(2):466-72. (PMID: 6309861)
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1776-1788. (PMID: 31022732)
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):110-20. (PMID: 24266581)
Adv Clin Exp Med. 2019 Nov;28(11):1561-1567. (PMID: 31596557)
J Biol Chem. 1994 Nov 11;269(45):27863-8. (PMID: 7961716)
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):. (PMID: 21576254)
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):151-61. (PMID: 11773026)
Trends Immunol. 2009 Jul;30(7):319-24. (PMID: 19541536)
Pharm Res. 2018 Apr 24;35(7):126. (PMID: 29691664)
Exp Eye Res. 2017 Dec;165:7-19. (PMID: 28860021)
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):153-8. (PMID: 14691167)
Cell Physiol Biochem. 2018;49(3):848-868. (PMID: 30184544)
Exp Eye Res. 1994 Dec;59(6):723-7. (PMID: 7698265)
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):2154-2166. (PMID: 29801150)
Invest Ophthalmol Vis Sci. 2013 Oct 17;54(10):6779-88. (PMID: 24030464)
J Cell Biol. 1993 Jun;121(5):1165-72. (PMID: 8501121)
Mol Vis. 2018 Oct 29;24:712-726. (PMID: 30429640)
J Biol Chem. 2005 May 13;280(19):18871-80. (PMID: 15677465)
Exp Eye Res. 2008 Apr;86(4):543-61. (PMID: 18313051)
J Biol Chem. 2002 Oct 4;277(40):37377-81. (PMID: 12145303)
Grant Information:
P30 EY016665 United States EY NEI NIH HHS; R01 EY017006 United States EY NEI NIH HHS; R01 EY026009 United States EY NEI NIH HHS; R01 EY026529 United States EY NEI NIH HHS
Substance Nomenclature:
0 (Fibronectins)
0 (Peptides)
0 (Transforming Growth Factor beta2)
0 (extra domain A fibronectin, mouse)
Entry Date(s):
Date Created: 20200822 Date Completed: 20201029 Latest Revision: 20201029
Update Code:
20240105
PubMed Central ID:
PMC7444551
DOI:
10.1371/journal.pone.0237932
PMID:
32822410
Czasopismo naukowe
Increased deposition of fibronectin fibrils containing EDA+fibronectin by TGFβ2 is thought to be involved in the reduction of aqueous humor outflow across the trabecular meshwork (TM) of the eye and the elevation in intraocular pressure (IOP) observed in primary open angle glaucoma (POAG). Using a fibronectin-binding peptide called FUD that can disrupt fibronectin fibrillogenesis, we examined if disrupting fibronectin fibrillogenesis would affect IOP in the TGFβ2 BALB/cJ mouse model of ocular hypertension. BALB/cJ mice that had been intravitreally injected with an adenovirus (Ad5) expressing a bioactive TGFβ2226/228 showed a significant increase in IOP after 2 weeks. When 1μM FUD was injected intracamerally into mice 2 weeks post Ad5-TGFβ2 injection, FUD significantly reduced IOP after 2 days. Neither mutated FUD (mFUD) nor PBS had any effect on IOP. Four days after FUD was injected, IOP returned to pre-FUD injection levels. In the absence of TGFβ2, intracameral injection of FUD had no effect on IOP. Western blotting of mouse anterior segments expressing TGFβ2 showed that FUD decreased fibronectin levels 2 days after intracameral injection (p<0.05) but not 7 days compared to eyes injected with PBS. mFUD injection had no significant effect on fibronectin levels at any time point. Immunofluorescence microscopy studies in human TM (HTM) cells showed that treatment with 2ng/ml TGFβ2 increased the amount of EDA+ and EDB+ fibronectin incorporated into fibrils and 2μM FUD decreased both EDA+ and EDB+ fibronectin in fibrils. An on-cell western assay validated this and showed that FUD caused a 67% reduction in deoxycholate insoluble fibronectin fibrils in the presence of TGFβ2. FUD also caused a 43% reduction in fibronectin fibrillogenesis in the absence of TGFβ2 while mFUD had no effect. These studies suggest that targeting the assembly of fibronectin fibrillogenesis may represent a way to control IOP.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies